The Listed Company Roadshow of the 2019 China BioMed Innovation and Investment Conference (2019 CBIIC) was successfully held on September 22nd and 23rd. The two-day roadshow sessions were moderated respectively by Kevin Xu, Senior Executive Director of Goldman Sachs (Asia) L.L.C., and Luo Jiarong, Chief Medical Analyst of Guangfa Securities. Travis Hu, Senior Director Head of Life Sciences of Greater China of Clarivate Analytics and Yuanjia Hu, Associate Professor of University of Macau and Deputy Director of Clinical Research Center of State Key Laboratory of Quality Research in Chinese Medicine made keynote speeches in each day’s roadshow. 15 innovative pharmaceutical companies from different capital markets, such as Chipscreen, BeiGene, Hua Medicine, Ascletis Bioscience, Cstone Pharmaceuticals, Shanghai Junshi Biosciences, Innovent Biologics, Xynomic Pharmaceuticals, Luye Pharma Group, Amoy Diagnostics, Tasly Holding Group, Xinbai Pharmaceutical, Betta Pharmaceutical, ZAI Lab, Haisco Pharmaceutical participated in the roadshow and introduced their business strategies, pipelines and visions for future market, which attracted numerous experts, scholars and investors.

Moderators
Kevin Xu, Senior Executive Director of Goldman Sachs (Asia) L.L.C. (left)
Luo Jiarong, Chief Medical Analyst of Guangfa Securities (right)

Listed Company Roadshow

Travis Hu, Senior Director Head of Life Sciences of Greater China of Clarivate Analytics, delivered a keynote speech titled “2018 Biopharma Deals & Portfolio Review and 2019 Drug to Watch”, he introduced the global pharmaceutical industry development trend from the aspects of M&A trends, current status of authorized cooperation, listing issues, VC and hot topics such as the approvals of new oncology drugs, value investing and the most noteworthy drugs in 2019.

Hu Yuanjia, Associate Professor of University of Macau and Deputy Director of Clinical Research Center of State Key Laboratory of Quality Research in Chinese Medicine, delivered a keynote speech titled “Patent Assets and Financial Performance of Pharmaceutical Companies: Evidence from Chinese and American Stocks”. He pointed out that China’s pharmaceutical industry is currently transforming from imitation to innovation, which is also the exact direction for pharmaceutical companies seeking updates. In the speech, he selected 100 sample companies of different scales from 5 major stock exchanges in China and the United States and made analysis using the hysteresis model of generalized estimation equation based on their patent indexes and financial data from 2009 to 2017 in a public database. The results showed that despite of the existent substantial regional variation, patent assets still exerting a significant impact on the financial performance of the listed pharmaceutical companies in both China and the United States. For pharmaceutical companies, there is a steady and significant positive correlation between new patent number and revenue.

Keynote Speakers
Left: Travis Hu, Senior Director Head of Life Sciences, Greater China, Clarivate Analytics
Right: Yuanjia Hu, Associate Professor, University of Macau / Deputy Director, Clinical Research Center, State Key Laboratory of Quality Research in Chinese Medicine

Lu Xianping, Chairman of Chipscreen Biosciences, Howard Liang, CFO & CSO of BeiGene, Chen Li, CEO of Hua Medicine, Richard Yeh, CFO of CStone Pharmaceuticals, Ronnie Ede, CFO of Innovent Biologics, Mark Xu, Chairman, CEO and President of Xymomic Pharma, Jiang Hua, Group Vice President of Luye Pharma Group, Zhu Guanshan, Executive Vice President of Amoy Diagnostics, Zhou ShuiPing, Executive Dirctor of TASLY Academy, Joe Du, Chief Strategy Officer, Head of Investor Relations, Vice President of Nanjing Cenbest, Lily Li, Senior Director, Strategic Collaboration of Betta Pharmaceuticals, Yang Liyuan, Director of Business Development and Business Strategy of Zai Lab, Zhou Feng, Director of BD &IP of Haisco Pharmaceutical Group, Yu Wenbing, GM Assistant of Shanghai Junshi Biosciences and Wang Yangming, Investor Relations Manager of Ascletis Bioscience introduced their companies’ global development strategy, new drug R&D status, missions, key products and market shares respectively.

Highlights of Roadshow Speakers
1st Row: Lu Xianping, Chairman of Chipscreen Biosciences, Howard Liang, CFO & CSO of BeiGene, Chen Li, CEO of Hua Medicine
2nd Row: Richard Yeh, CFO of CStone, Ronnie Ede, CFO of Innovent Biologics, Mark Xu, Chairman, CEO and President of Xymomic Pharma,
3rd Row: Jiang Hua, Group Vice President of Luye Pharma Group, Zhu Guanshan, Executive Vice President of Amoy Diagnostics, Zhou ShuiPing, Executive Dirctor of TASLY Academy,
4th Row: Joe Du, Chief Strategy Officer, Head of Investor Relations, Vice President of Nanjing Cenbest, Lily Li, Senior Director, Strategic Collaboration of Betta Pharmaceuticals, Yang Liyuan, Director of Business Development and Business Strategy of Zai Lab
5th Row: Zhou Feng, Director of BD &IP of Haisco Pharmaceutical Group, Yu Wenbing, GM Assistant of Shanghai Junshi Biosciences and Wang Yangming, Investor Relations Manager of Ascletis Bioscience

On the roadshow, the panel of “Sustainable Development of Innovative Biopharma Companies in China” was successfully held and hosted by Kevin Xu, Senior Executive Director of Goldman Sachs (Asia) L.L.C.

Panel: “Sustainable Development of Innovative Biopharma Companies in China”
From left to right: Kevin Xu, Lu Xianping, Chairman, General Manager and Chief Scientist of Chipscreen
 Chen Li, CEO, Hua Medicine
Richard Yeh, Chief Financial Officer of CStoneLi Ning, ED, CEO of Shanghai Junshi Biosciences
Ronnie Ede, CFO of Innovent

The success of the four-time Listed Company Roadshows has witnessed the rapid growth of China’s innovative pharmaceutical industry since 2015 in the context of constantly deepening the drug administration reform and optimizing the innovation environment, as well as the innovative R&D trend that transformed China from the power of imitation to innovation. It has also witnessed the role of capital market with opening policies in promoting the development of pharmaceutical industry, such as the implementation of the new pre-revenue biotech IPO Policy of HKEX and the launch of the SSE STAR Market. Through keynote speeches and roadshows mentioned above, the participants were able to have a more in-depth understanding of the listed companies in strategic layout, innovative areas and R&D pipelines. Those extraordinary ideas did  not only help the investors better seek the investment objective and area, but also the start-up innovative R&D enterprises to learn more about the listing layout and gain experience of development and seek better opportunities for cooperation. The company representatives and participants gave high praise for the Listed Company Roadshow and appreciated PhIRDA for providing a platform of communication, cooperation and investment of pharmaceutical industries.